KPC Pharmaceuticals Inc Market Cap ($981.42 Million)
Market Cap & Net Worth: KPC Pharmaceuticals Inc (600422)
KPC Pharmaceuticals Inc market cap. KPC Pharmaceuticals Inc (SHG:600422) has a market capitalization of $981.42 Million (CN¥6.71 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #8671 globally and #2034 in its home market, demonstrating a 3.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KPC Pharmaceuticals Inc's stock price CN¥8.86 by its total outstanding shares 756975757 (756.98 Million). Also see KPC Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
KPC Pharmaceuticals Inc Market Cap History (2015–2026)
KPC Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $1.93 Billion to $981.42 Million (-4.90% CAGR). Check 600422 share price today for real-time trading data and today's change.
KPC Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KPC Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600422 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.21x
KPC Pharmaceuticals Inc's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.98x
KPC Pharmaceuticals Inc's market cap is 3.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.35 Billion | $5.10 Billion | $407.26 Million | 0.26x | 3.31x |
| 2017 | $926.88 Million | $5.85 Billion | $330.10 Million | 0.16x | 2.81x |
| 2018 | $626.02 Million | $7.10 Billion | $335.54 Million | 0.09x | 1.87x |
| 2019 | $1.10 Billion | $8.12 Billion | $454.31 Million | 0.14x | 2.42x |
| 2020 | $904.63 Million | $7.72 Billion | $456.86 Million | 0.12x | 1.98x |
| 2021 | $1.19 Billion | $8.25 Billion | $507.67 Million | 0.14x | 2.34x |
| 2022 | $1.55 Billion | $8.28 Billion | $383.18 Million | 0.19x | 4.05x |
| 2023 | $2.31 Billion | $8.43 Billion | $540.71 Million | 0.27x | 4.27x |
| 2024 | $1.76 Billion | $8.40 Billion | $648.08 Million | 0.21x | 2.71x |
| 2025 | $1.39 Billion | $6.58 Billion | $349.94 Million | 0.21x | 3.98x |
Competitor Companies of 600422 by Market Capitalization
Companies near KPC Pharmaceuticals Inc in the global market cap rankings as of November 8, 2026. Also see how large is KPC Pharmaceuticals Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to KPC Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of KPC Pharmaceuticals Inc (2015–2026)
Market capitalization of KPC Pharmaceuticals Inc from 2015 to today. Between 2015 and today, KPC Pharmaceuticals Inc's market cap moved from $1.93 Billion to $ 981.42 Million, with a yearly change of -4.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥981.42 Million | -29.46% |
| 2025 | CN¥1.39 Billion | -20.76% |
| 2024 | CN¥1.76 Billion | -24.02% |
| 2023 | CN¥2.31 Billion | +48.99% |
| 2022 | CN¥1.55 Billion | +30.79% |
| 2021 | CN¥1.19 Billion | +31.08% |
| 2020 | CN¥904.63 Million | -17.72% |
| 2019 | CN¥1.10 Billion | +75.62% |
| 2018 | CN¥626.02 Million | -32.46% |
| 2017 | CN¥926.88 Million | -31.16% |
| 2016 | CN¥1.35 Billion | -30.18% |
| 2015 | CN¥1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of KPC Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $981.42 Million USD |
| MoneyControl | $981.42 Million USD |
| MarketWatch | $981.42 Million USD |
| marketcap.company | $981.42 Million USD |
| Reuters | $981.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, ant… Read more